Early Life Programming of Impaired Neurocognitive Function—What Does It Mean for Public Health?

• by Peter M. Nilsson

• October 29, 2026

FDA, CMS target gene therapy barriers

FDA and CMS initiatives aim to simplify gene therapy approvals and expand access to treatments for rare diseases.

• by Mouj Hijazi

• October 29, 2026

• 4 min

Renal outcome at 2 years in neonates with nephrocalcinosis and bronchopulmonary dysplasia: a case–control study

• by Andrew Wade, Sumesh Thomas, Andrew Walker, Nahid Arjmand Kermani, Carlos Fajardo

• October 15, 2026

Shockwave therapy may aid early return to sport

A 14-year-old soccer player achieved fracture consolidation and clearance for unrestricted sports participation at 8 weeks, although the treatment's contribution remains uncertain.

• by Andrea Surnit

• October 19, 2026

• 3 min